Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: Indications and efficacy of a differentiated approach

Journal of Endourology

Volumn 21, Issue 12, 2007, Pages 1533-1541

  Schulze, Michael ^a,b   Stotz, Nicoletta ^a   Rassweiler, Jens ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SLK Kliniken Heilbronn GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECOND LOOK SURGERY; SUPERFICIAL CANCER; SURGICAL APPROACH; SURGICAL TECHNIQUE; TRANSURETHRAL RESECTION;

ADMINISTRATION, INTRAVESICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; CYSTOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 38049152945     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2007.9866     Document Type: Article

References (47)

1. Göl S. Langzeitstudie nach transurethraler Resektion bei oberflächlichen Harnblasentumoren unter Berücksichtigung der Rezidiv- und Progressionsrate. Med. Diss. Mannheim, Heidelberg: 2002.
2. Klän R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991;146:316-318.
3. Mayr E, Klöpper W, Maier G, Blech M. Transurethrale Resektion von Harnblasentumoren Bedeutung einer zweiten Sitzung. Urologe B 1989;29:230-231.
4. Flamm J, Steiner R. [The value of differentiated transurethral resection in primary superficial bladder cancer] (Ger). Urologe A 1991;30:111-113.
5. Vögeli TA, Marx G, Ackermann R. Zur Notwendigkeit der Nachresektion beim urothelialen Blasen-Ca als Kontrolle der Erstresektion. Urologe A 1992;31(suppl):59.
6. Koloszy Z. Histopathological "self control" in transurethral resection of bladder tumors Br J Urol 1991;67:162-164.
7. Vögeli TA, Grimm MO, Simon X, Ackermann R. [Prospective study of effectiveness. Reoperation (re-TUR) in superficial bladder carcinoma.] (Ger) Urologe A 2002;41:470-474.
8. Köhrmann KU, Wöste M, Kappes J, Rassweiler J, Alken P. Der Wert der transurethralen Nachresektion bei oberflächlichen Harnblasenkarzinomen. Akt Urol 1994;25:208-213.
9. Mersdorf A, Brauers A, Wolff JM, Schneider V, Jakse G. Second transurethral resection for superficial bladder cancer. A must? J Urol 1998;159(suppl):A143.
10. Morrison AS, Verhoek WG, Leck I, Aoki K, Ohno Y, Obata K. Artificial sweeteners and bladder cancer in Manchester, U.K., and Nagoya, Japan. Br J Cancer 1982;45:332-336.
11. Engelhardt PF, Simak R, Daha LK, Plas E, Pflüger H. Die Wertigkeit der 2nd look transurethralen Elektroresektion beim oberflächlichen Blasenkarzinom. Akt Urol 2001;32:173-177.
12. Schips L, Augustin H, Zigeuner RE, Gallé G, Habermann H, Trummer H, Pummer K, Hubmer G. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59:220-223.
13. Stöckle M. Kommentar zu Köhrmann, et al. "Der Wert der transurethralen Nachresektion beim oberflächlichen Harnblasenkarzinom" . Akt Urol 1994;25:212-213.
14. Krege S, Giani G, Meyer R, Otto T, Rübben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. J Urol 1996;156:962-966.
15. Kurth KH, Bouffioux C, Sylvester R, van der Meijden APM, Oosterlinck W, Brausi M.Treatment of superficial bladder cancer tumors: Achievements and needs. Eur Urol 2000;37(suppl 3):1-9.
16. Murphy WM, Soloway MS, Crabtree WN. The morphologic effects of mitomycin C in mamillian urinary bladder. Cancer 1981;47:2567-2574.
17. Prout GR Jr. Dynamic evaluation of bladder cancer. In: Denis L, Smith PH, Pavone-Macaluso, eds. Clinical Bladder Cancer. New York-London: Plenum Press; 1982:61-69.
18. Soloway MS. The management of superficial bladder cancer . Cancer 1980;45(suppl 7):1856-1865.
19. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993;150:60-64.
20. Althausen AF, Prout GR Jr, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976;116:575-580.
21. Dalesio O, Schulman CC, Sylvester R, De Pauw M, Robinson M, Denis L, Smith P, Viaggiano G. Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. J Urol 1983;129:730-733.
22. Flamm J, Havelec L, Donner G. Die Effektivität der adjuvanten topischen Doxorubicin-Therapie auf die Rezidivhäufigkeit beim primären oberflächlichen Blasenkarzinom Urologe A 1992;59(suppl).
23. Hassler H, Bandhauer K: Lokalrezidiv oder Neutumor - Indikator für Prognose und Therapie beim oberflächlichen Blasencarcinom. Urologe A 1992;31(suppl):59.
24. Heney NM, Nocks BN, Daly JJ, Prout GR Jr, Newall JB, Griffin PP, Perrone TL, Szyfelbein WA. Ta and T1 bladder cancer: Location, recurrence and progression. Br J Urol 1982;54:152-157.
25. Lutzeyer W, Rübben H, Dahm H. Prognostic parameters in superficial bladder cancer: An analysis of 315 cases. J Urol 1982;127:250-252.
26. Kiemeney LA, Witjes JA, Heijbroek RP, Koper NP, Verbeek AL, Debruyne FM. Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Members of the Dutch South-East Co-operative Urological Group. Br J Urol 1994;73:164-171.
27. Loening S, Narayana A, Yoder L, Slymen D, Penick G, Culp D. Analysis of bladder tumor recurrence in 178 patients. Urology 1980;16:137-141.
28. Narayana AS, Loening SA, Slymen DJ, Culp DA. Bladder cancer: Factors affecting survival. J Urol 1983;130:56-60.
29. Rassweiler J, Hath U, Bub P, Eisenberger F. Intravesikale Langzeitchemoprophylaxe mit Mitomycin C beim oberflächlichen Harnblasenkarzinom - Rezidivverhalten und Progression nach 3 Jahren. Akt Urol 1988;19:139-144.
30. Shinka T, Matsumoto M, Ogura H, Hirano A, Ohkawa T. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guerin: A longterm follow-up. Int J Urol 1997;4:139-143.
31. Witjes JA, Kiemeney LA, Schaafsma HE, Debruyne FM. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Br J Urol 1994;73:172-176.
32. Witjes JA, Kiemeney LALM, Verbeek AL, et al. Random bladder biopsies and the risk of recurrent superficial bladder cancer: A prospective study in 1026 patients. World J Urol 1992:10:231.
33. Kurth KH, Denis L, Bouffioux C, Sylvester R, Debruyne FM, Pavone Macoluso M, Oosterlinck W. Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer 1995;31A:1840-1846.
34. Pearson RM, Soloway MS. Does cyclophosphamide induce bladder cancer? Urology 1978;11:437-447.
35. Otto T, Rübben H. Carcinoma in situ of the urinary bladder - definition and status of treatment. Urologe A 1991;30:163-166.
36. Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organisation for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993;149:749-752.
37. Vögeli TA, Grimm O, Ackermann R. Prospective study for quality control of TUR of bladder tumors by routine 2nd TUR. J Urol 1998;159(suppl):143.
38. Birch BR, Harland SJ. The pT1 G3 bladder tumour. Br J Urol 1989;64:109-116.
39. Jakse G, Algaba F, Malmström PU, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: Why? Eur Urol 2004;45:539-546.
40. Lundbeck F, Jacobsen T, Vaeth M. Impact of the category of early tumor recurrence on tumor progression in bladder tumors treated by transurethral resection. Eur Uro 1989;16:291-294.
41. Mulders PF, Meyden AP, Doesburg WH, Oosterhof GO, Debruyne FM. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Cooperative Group. Br J Urol 1994;73:403-408.
42. Sözen S, Akbal C, Sökmensüer C, Ekici S, Özen H. Microstaging of pT1 transitional cell carcinoma of the urinary bladder. Does it really differentiate two populations with different prognoses? Urol Int 2002;69:200-206.
43. Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: Is cystektomy often too early? J Urol 2001;165:808-810.
44. Wolf H, Iversen HG, Rosenkilde P, Schröder T. Transurethral surgery in the treatment of the invasive bladder cancer (T1 and T2). Scand J Urol Nephrol 1987;104:127-132.
45. Hautmann RE, Miller K, Steiner U, Wenderoth U: The ileal neobladder: 6 years of experience with more than 200 patients. J Urol 1993;150:40-45.
46. Stöckle M, Alken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R. Radical cystectomy - often too late? Eur Urol 1987;13:361-367.
47. Cheng L, Neumann RM, Weaver AL, ,et al. Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cysectomy specimens. Am J Clin Pathol 2000;113:275-279.